LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Reaffirmed by Roth Mkm

LeMaitre Vascular (NASDAQ:LMATGet Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Roth Mkm in a research report issued on Friday, Marketbeat reports. They currently have a $100.00 price target on the medical instruments supplier’s stock. Roth Mkm’s price target would indicate a potential upside of 26.77% from the stock’s previous close.

Several other equities research analysts have also issued reports on the stock. Barrington Research increased their target price on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. JMP Securities raised their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. KeyCorp started coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating on the stock. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their price target for the stock from $59.00 to $75.00 in a report on Friday, April 26th. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.57.

View Our Latest Stock Analysis on LMAT

LeMaitre Vascular Stock Up 0.1 %

Shares of LMAT opened at $78.88 on Friday. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 52.24, a PEG ratio of 2.40 and a beta of 0.88. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $81.68. The stock’s 50-day moving average price is $70.37 and its 200-day moving average price is $62.91.

LeMaitre Vascular (NASDAQ:LMATGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The business had revenue of $53.48 million for the quarter, compared to analysts’ expectations of $51.50 million. During the same quarter last year, the company earned $0.27 EPS. The business’s revenue was up 13.6% on a year-over-year basis. As a group, equities analysts anticipate that LeMaitre Vascular will post 1.78 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Bridget A. Ross sold 5,500 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $77.99, for a total value of $428,945.00. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at $177,661.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director John A. Roush sold 7,500 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $69.00, for a total value of $517,500.00. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at $157,182. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridget A. Ross sold 5,500 shares of LeMaitre Vascular stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $77.99, for a total transaction of $428,945.00. Following the transaction, the director now directly owns 2,278 shares in the company, valued at $177,661.22. The disclosure for this sale can be found here. Insiders have sold 136,641 shares of company stock valued at $9,979,843 in the last ninety days. 10.79% of the stock is currently owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Several institutional investors have recently made changes to their positions in LMAT. YHB Investment Advisors Inc. acquired a new stake in LeMaitre Vascular during the first quarter worth $36,000. DekaBank Deutsche Girozentrale purchased a new stake in LeMaitre Vascular in the 3rd quarter valued at about $38,000. SRS Capital Advisors Inc. raised its holdings in LeMaitre Vascular by 325.5% in the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 524 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new stake in LeMaitre Vascular in the 1st quarter valued at about $206,000. Finally, Whitegate Investment Counselors Inc. purchased a new position in LeMaitre Vascular during the first quarter worth about $216,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Featured Articles

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.